Drug intelligence / Profile preview

liver extract + flavin adenine dinucleotide

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

Liver extract + flavin adenine dinucleotide is a combined preparation that has been widely used in patients with chronic liver diseases, particularly in Japan. One milliliter of this agent contains 15 microliters of phenol-soluble phase of liver nucleic acid fraction and 10 mg of flavin adenine dinucleotide (FAD). This combination appears to enhance the anti-viral efficacy of interferon (IFN) in patients with chronic hepatitis C by increasing 2'5'-oligoadenylate synthetase (2'5-AS) production, possibly as a result of increased mitochondrial adenosine triphosphate production.

Brand names: Adelavin

Targets

OAS (2'-5'-oligoadenylate synthase)

Beyond the preview

Go deeper on liver extract + flavin adenine dinucleotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on liver extract + flavin adenine dinucleotide.

Explore the full profile